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a IranA majority of acute pericarditis cases have some degree of myocarditis. Viruses are the common etiological factor of
this disease. Corticosteroids are considered for treatment, especially in recurrent models of the disease. In this article,
we report the case of a 47-year-old man with myopericarditis who was under daily intra-muscular dexamethasone
injection for an unknown reason. This is a unique case of spontaneous myopericarditis under corticosteroid abuse that
has not been reported previously.
 2015 The Author. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Myopericarditis, CorticosteroidsIn the majority of cases, acute pericarditis hassome degree of myocarditis because viruses
are the common etiological factor for both dis-
eases [1]. History of a febrile syndrome accompa-
nied by pleuritic chest pain, fatigue, and
decreased exercise capacity is the most common
scenario for this disease. Principle findings on
electrocardiogram (ECG) are diffuse ST-elevation
(typically concave up) and depression of the PR
segment, especially in V5 and V6 leads. High
levels of Troponin and CK-MB due to myocardial
injury are detected in laboratory findings.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)are the cornerstone of therapy. Besides conven-
tional treatments, colchicine also has positive
effects. Due to their anti-inflammatory effects, cor-
ticosteroids should be considered in treatment,
especially for recurrent models of the disease [2].
Herein, we report a unique spontaneous case of
myopericarditis in a patient subjected to corticos-
teroid therapy.
A 47-year-old man presented at the emergency
department with acute left hemithorax pain and
dyspnea. Bending forward was the only condition
which improved his pain. No cardiac risk factor,
such as diabetes mellitus, hypertension or
smoking were found in his medical history. Over
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UNDER DEXAMETHASONE: A DOUBLE-EDGED SWORD?a period of four months, he was self-administering
daily intra-muscular dexamethasone injections
without physician prescription. Lower extremities
had 3+ pitting edema. His electrocardiogram
showed diffused ST-elevation in all leads except
in V1 and aVR (Fig. 1). Cardiac Troponin I
was positive for three times at the ranges of
2.86, 2.68 and 1.89, respectively (normal 60.01).
Echocardiography revealed mild to moderate
pericardial effusion with lateral and posterior wall
hypokinesia. No valvular involvement was seen.
Pulmonary artery pressure was about 25 mmHg.
Ejection fraction was estimated at 25–30%.
Ibuprofen 600 mg three times a day along with
heart failure treatment (ACEI/ARB, B-blocker)
was started, stress dose of corticosteroid was
administered and dexamethasone was tapered.
Dramatic response was seen after two days. This
patient underwent coronary angiography, and no
significant lesion was noted. Workup was per-
formed to rule out secondary causes for myoperi-
carditis. All, including Antinuclear Antibody
(ANA), double stranded DNA (dsDNA),
Rheumatoid Factor (RF), Cyclic Citrullinated
Peptide Antibody (AntiCCP), Perinuclear Anti-
Neutrophil Cytoplasmic Antibody (P-ANCA) and
Antineutrophil cytoplasmic antibody (C-ANCA),
were in normal range or negative. Ferritin level,
TFT, serum and urine electrophoresis were also
in normal range. PPD test was negative. After
two years’ follow up, echocardiography revealed
ejection fraction at 35–40%. No recurrence was
seen to present day.The past decades have seen steroids being uti-
lized for the prevention of myopericarditis
relapse. The main mechanism is not well under-
stood but it seems that immune modulation and
suppression induced by corticosteroids play a cru-
cial role [3]. In NSAID-resistant patients and in
relapsing cases, corticosteroids should be consid-
ered. Recent recommendations limit the role of
corticosteroids due to the lack of clinical evidence
regarding medium and long-term benefits [4]. The
use of corticosteroid therapy for recurring peri-
carditis is supported solely by a retrospective
study [3]. Some studies have demonstrated that
high dose corticosteroid not only leads to major
side effects, but also to hospitalization and recur-
rent pericarditis. As corticosteroids promote viral
replication, they have been reported as indepen-
dent risk factors for further recurrences in the first
episode or after two or more recurrences [5]. In
our case, all secondary reasons for myopericarditis
were assessed, and no specific etiology was found.
Coronary angiography revealed normal findings.
With echocardiography, and electrocardiographic
and cardiac injury markers, myopericarditis was
the first diagnosis for our patient. As our patient
was under dexamethasone for four months, we
expected that in a previously healthy individual
under dexamethasone, pericarditis would occur
in a subtle form or would not occur due to anti-in-
flammatory effects. It seems that corticosteroids
are not an effective therapy for acute myoperi-
carditis or may be an etiology for myopericarditis.
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response is suppressed by dexamethasone, car-
diotropic viruses involve the pericardium and
myocardium by direct cytolytic or cytotoxic effects.
Abnormal immune response triggered by the
viruses or corticosteroids in the presence of a pre-
disposing genetic background is the main mecha-
nism of myocardial damage in the absence of a
viral genome. After cessation of corticosteroid
over two years, no recurrence was seen in our
patient. This article is congruent with other studies
against corticosteroid efficacy in myopericarditis.
Although viral agents could not be ruled out, it
seems that dexamethasone is an etiologic or exac-
erbating agent in our case. We recommend that
corticosteroids be omitted from myopericarditis
treatment lists. Nevertheless, larger controlled
trials are needed to investigate the role of dexam-
ethasone in acute myopericarditis.References
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